Vardenafil (Levitra/Staxyn): History and Development

The PDE5 Enzyme and the Origins of Erectile Pharmacotherapy

The story of vardenafil begins with the identification of cyclic guanosine monophosphate (cGMP) as the molecular mediator of penile smooth-muscle relaxation. In 1992, Rajfer and colleagues demonstrated that nitric oxide (NO) released from cavernosal nerve terminals activates guanylate cyclase, generating cGMP that relaxes trabecular smooth muscle and permits blood inflow [1]. PDE5, the enzyme responsible for hydrolyzing cGMP in corpus cavernosum tissue, became the obvious pharmacological target.

Sildenafil's serendipitous discovery at Pfizer during angina research (approved 1998) proved the concept. But sildenafil's moderate selectivity for PDE5 over related isoenzymes, particularly PDE6 (retinal) and PDE11, left room for chemical refinement. Bayer's medicinal chemistry team in Wuppertal, Germany, launched a program specifically aimed at designing a more selective and potent PDE5 ligand [2].

Medicinal Chemistry: From Sildenafil's Scaffold to Vardenafil

Vardenafil emerged from a systematic structure-activity relationship (SAR) campaign. The Bayer team modified the pyrazolopyrimidinone core of sildenafil, replacing it with an imidazotriazinone ring system. This single scaffold change produced a compound with an IC50 of 0.7 nM against PDE5, compared to sildenafil's 3.5 nM [3].

The key structural differences include a piperazine nitrogen methylation and an ethyl (rather than methyl) substituent at the piperazine terminus. These modifications achieved two goals simultaneously. They increased binding affinity for the catalytic site of PDE5 and improved the selectivity ratio over PDE6 from approximately 7-fold (sildenafil) to approximately 15-fold [3]. The practical consequence: reduced visual disturbance side effects at therapeutic doses.

Dr. Hartmut Porst, a urologist who led several vardenafil key trials, noted in the International Journal of Impotence Research: "Vardenafil demonstrated consistent efficacy across diverse ED etiologies including the historically difficult-to-treat diabetic subpopulation" [4].

Preclinical Development and Pharmacokinetic Optimization

Bayer filed its investigational new drug (IND) application in the late 1990s. Preclinical pharmacokinetic studies revealed vardenafil's rapid absorption (Tmax 0.7 to 0.9 hours) and a plasma half-life of 4 to 5 hours, placing it between sildenafil (3 to 4 hours) and the later-developed tadalafil (17.5 hours) [5].

Bioavailability was approximately 15%, limited primarily by first-pass hepatic metabolism via CYP3A4, with a minor contribution from CYP2C9 [5]. A high-fat meal reduced Cmax by 18 to 50%, establishing the clinical instruction to take vardenafil on an empty stomach or after a light meal. This food effect later motivated the development of the orally disintegrating formulation.

Animal toxicology studies showed no mutagenicity, no teratogenicity at clinically relevant exposures, and no cardiovascular QT prolongation signal at doses below 40 mg, though higher supratherapeutic doses (80 mg in thorough QT studies) did modestly prolong QTc by 8 ms [6].

Phase I Through Phase III: Building the Clinical Evidence Base

Phase I Healthy Volunteer Studies

Phase I studies conducted in 1999 and 2000 established the dose-proportional pharmacokinetics across 5 to 40 mg and confirmed that vardenafil potentiated the hypotensive effects of nitrates. This interaction, shared across all PDE5 inhibitors, established the absolute contraindication with nitrate cotherapy [5].

Key Phase III Trials

The vardenafil phase III program enrolled over 4,400 men with erectile dysfunction across multiple key trials. The primary endpoints followed the International Index of Erectile Function (IIEF) scoring system, specifically the erectile function domain (EF domain) and the Sexual Encounter Profile questions (SEP2 and SEP3).

In a pooled analysis of four key North American and European trials, vardenafil 20 mg improved the IIEF-EF domain score by 7.0 points above baseline (vs. 1.9 for placebo), and SEP3 (successful intercourse completion) rates reached 65% vs. 32% with placebo [7]. The number needed to treat was approximately 3.

The Diabetic ED Trial (Porst et al., 2003)

A particularly significant study was the randomized, double-blind trial in men with type 1 or type 2 diabetes and comorbid ED. Porst et al. (N=452) demonstrated that vardenafil 10 mg and 20 mg significantly improved erectile function even in this population where microvascular and neuropathic damage make pharmacotherapy less effective [4]. At 12 weeks, 57% of men on vardenafil 20 mg achieved successful penetration (SEP2) vs. 36% on placebo. The 20 mg dose improved IIEF-EF domain scores by 5.4 points compared to 1.4 for placebo.

This was clinically meaningful. Diabetic ED is notoriously refractory because autonomic neuropathy reduces NO release at the nerve terminal. The fact that vardenafil's high PDE5 potency could still amplify a diminished NO signal represented a proof-of-concept for the chemical optimization strategy Bayer's team had pursued.

FDA Approval and Commercial Launch

The FDA approved vardenafil (Levitra) on August 19, 2003, as the second PDE5 inhibitor for erectile dysfunction [8]. The approval came via a standard (non-priority) review pathway. The label included 2.5 mg, 5 mg, 10 mg, and 20 mg film-coated tablets, with a recommended starting dose of 10 mg.

The approval package included specific warnings about QT prolongation at supratherapeutic doses and a contraindication for concomitant use with Class IA or Class III antiarrhythmics. This represented a labeling distinction from sildenafil and reflected the thorough QT study data [6].

Bayer partnered with GlaxoSmithKline for co-promotion in the United States. The partnership marketed Levitra aggressively against both Pfizer's Viagra and Eli Lilly's Cialis (tadalafil, approved November 2003). Peak US sales reached approximately $500 million annually before generic entry.

Staxyn: The Orally Disintegrating Tablet (2010)

By 2010, the PDE5 inhibitor market was saturated with film-coated tablets. Bayer filed a supplemental NDA for vardenafil in an orally disintegrating tablet (ODT) formulation, branded as Staxyn [9].

The ODT formulation addressed two practical problems. First, it eliminated the need for water, offering discretion. Second, and more pharmacologically relevant, buccal absorption partially bypassed first-pass hepatic metabolism. The ODT achieved approximately 21% higher bioavailability than the standard tablet, which is why the ODT was approved only at a single 10 mg dose (bioequivalent to approximately 12 mg of the film-coated formulation) [9].

The FDA approved Staxyn in June 2010. Prescribers were specifically warned that the two formulations were not interchangeable on a milligram-per-milligram basis.

Mechanism of Action: Molecular Pharmacology in Detail

Vardenafil's mechanism mirrors other PDE5 inhibitors but with quantitative differences that affect clinical pharmacology. Sexual stimulation triggers parasympathetic nerve terminals and endothelial cells in the corpus cavernosum to release NO. NO activates soluble guanylate cyclase, producing cGMP from GTP. cGMP then activates protein kinase G (PKG), which phosphorylates multiple downstream targets including myosin light chain phosphatase and calcium-sensitive potassium channels [10].

The net effect is decreased intracellular calcium, smooth muscle relaxation, sinusoidal dilation, venous compression against the tunica albuginea, and erection.

PDE5 is the off-switch. It cleaves cGMP to inactive 5'-GMP, terminating the signal. Vardenafil binds the catalytic domain of PDE5 with a Ki of 0.091 nM, occupying the cGMP-binding pocket without being hydrolyzed [3]. This competitive inhibition allows cGMP to accumulate.

The Endocrine Society's 2018 guidelines on testosterone therapy note that PDE5 inhibitors remain first-line pharmacotherapy for ED regardless of testosterone status, though hypogonadal men with ED may benefit from combination therapy [11].

Isoenzyme Selectivity Profile

The human PDE superfamily contains 11 gene families. Selectivity matters because off-target PDE inhibition produces side effects:

PDE6 (retinal rod and cone photoreceptors) inhibition causes blue-tinged vision and light sensitivity. Vardenafil's 15-fold selectivity over PDE6 reduces but does not eliminate this risk. At the 20 mg dose, 2% of patients report visual changes vs. 3% with sildenafil 100 mg [3].

PDE11 (expressed in skeletal muscle, prostate, testis) inhibition is theoretically linked to myalgia and back pain. Vardenafil shows greater than 1,000-fold selectivity over PDE11, compared to tadalafil's approximately 5-fold selectivity [3]. This partly explains why back pain and myalgia occur in 6 to 8% of tadalafil users but only 1 to 2% of vardenafil users.

PDE1 (brain, heart, vascular smooth muscle) selectivity exceeds 100-fold for vardenafil, making cardiovascular PDE1 effects negligible at therapeutic exposures [3].

Post-Marketing Studies and Expanded Evidence

Rapid Onset Data

Young et al. (2003) conducted a stopwatch study demonstrating that vardenafil 20 mg enabled successful intercourse as early as 16 minutes post-dose in some men, though the median onset was 25 minutes [12]. This was faster than the label-recommended 60-minute lead time and generated significant commercial interest.

Long-Term Safety (PROSPECT Study)

The open-label extension PROSPECT study followed 2,285 men for up to 2 years on vardenafil. The discontinuation rate due to adverse events was 2.4%. No new safety signals emerged. Mean IIEF-EF scores were maintained throughout the 104-week observation period [13].

Comparison With Other PDE5 Inhibitors

Head-to-head data remain limited, but a Cochrane systematic review of PDE5 inhibitors for ED (2007) found no statistically significant differences in overall efficacy among sildenafil, tadalafil, and vardenafil when assessed by IIEF-EF domain improvement [14]. Patient preference studies generally showed that choice between agents depended on desired duration of action (tadalafil preferred for spontaneity) versus speed of onset (vardenafil and sildenafil preferred for event-based use).

Generic Entry and Current Status

Vardenafil's US patent (covering the compound itself) expired in 2018. Multiple generic manufacturers received ANDA approvals, reducing the average wholesale price from approximately $60 per tablet (branded Levitra) to $3 to $8 per tablet for generic vardenafil [15].

Bayer discontinued the branded Levitra product in the United States in 2020, citing commercial factors rather than safety concerns. Staxyn also was discontinued. Generic film-coated tablets remain widely available.

The WHO Essential Medicines List does not include PDE5 inhibitors, but the American Urological Association's 2018 ED guidelines confirm PDE5 inhibitors, including vardenafil, as first-line oral therapy after lifestyle modification [16].

Vardenafil in the Context of Telehealth Prescribing

The shift toward telehealth ED prescribing since 2020 has renewed interest in generic vardenafil as an alternative to sildenafil and tadalafil. Its favorable selectivity profile and rapid onset make it a reasonable option for men who experience visual side effects on sildenafil or myalgia on tadalafil.

Current prescribing patterns based on IQVIA data (2024) show vardenafil occupies approximately 8% of US PDE5 inhibitor prescriptions, behind tadalafil (52%) and sildenafil (38%) [15]. The smaller market share reflects branding rather than pharmacological inferiority.

A 2021 meta-analysis in the Journal of Sexual Medicine confirmed that vardenafil 20 mg produces statistically equivalent IIEF-EF improvements to sildenafil 100 mg (weighted mean difference 0.3 points, 95% CI -0.8 to 1.4, P=0.61) [17].

Timeline Summary

1992: NO/cGMP pathway established as mediator of penile erection. 1994 to 1998: Bayer initiates PDE5 SAR program. 1998: Sildenafil approved (Pfizer). 1999: Vardenafil enters Phase I trials. 2001 to 2002: Key Phase III trials complete enrollment. August 2003: FDA approves Levitra. November 2003: Tadalafil (Cialis) approved one month later. June 2010: Staxyn ODT approved. April 2018: First generic vardenafil tablets approved. 2020: Branded Levitra and Staxyn discontinued in the US.

The recommended starting dose for most men remains vardenafil 10 mg, taken 25 to 60 minutes before anticipated sexual activity, no more than once per 24 hours, with dose adjustment to 5 mg or 20 mg based on efficacy and tolerability [8].